| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4f30c3245cdacedd986abee887cdca25 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1652
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1617
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1623
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1694
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-167
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-717 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-436 |
| filingDate |
2020-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5af62d2fab3e400629865e0f47fcd327
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67fcd1f8356914b9360254c936679bbc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_918cf59b5b11a290cd7de2be7fb1d8c4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5d95d1f9cbd37a4d6c9122ae7db30d0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0047ab1af235a5a0357cdc3f2a6a17b3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59bbdaa86bdd9c3d0eedc900d46568db |
| publicationDate |
2020-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-202045166-A |
| titleOfInvention |
Oral composition, method for manufacturing, and use thereof |
| abstract |
An oral composition includes an immediate-release pharmaceutical admixture and an extended-release pharmaceutical admixture. The immediate-release pharmaceutical admixture includes a first portion of an active ingredient and a first portion of a hydrophilic dispersant, in which the active ingredient is substantially insoluble in water. The extended-release pharmaceutical admixture includes a controlled-release material, a second portion of the active ingredient, and a second portion of the hydrophilic dispersant, wherein the second portion of the active ingredient and the second portion of the hydrophilic dispersant are mixed in the controlled-release material, wherein the active ingredient is present as a nanoparticle in the immediate-release pharmaceutical admixture and the extended-release pharmaceutical admixture. The method for manufacturing an oral composition and use of an oral composition for treatment of a symptom or a disease caused by immune response or for treatment of organ rejection are further provided. |
| priorityDate |
2019-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |